Ocata Therapeutics Announces New Pre-Clinical Data to be Reported at
the International Congress on Systemic Lupus Erythematosus

Promising Potential Therapeutic Activity from the Company’s
Proprietary HMC™ Platform to be presented in Vienna, Austria on
September 4, 2015

July 14, 2015 08:30 AM Eastern Daylight Time

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a
leader in the field of Regenerative OphthalmologyTM,
announced today that data will be presented at the 11th International
Congress on Systemic Lupus Erythematosus, taking place in Vienna,
Austria from September 2-6.

The results demonstrate promising potential therapeutic activity of
a pluripotent stem cell-derived product for the treatment of autoimmune
diseases such as lupus nephritis and Crohn's disease using Ocata’s
proprietary Hemangio-derived Mesenchymal Cell (HMCTM)
platform. This unique and proprietary HMC product has been shown to
have highly potent immune-modulatory and anti-inflammatory activity and
is potentially well-suited for commercial scale up with retention of
therapeutic potency.

The data describes both ex-vivo and in-vivo evidence in a
highly regarded pre-clinical model of lupus nephritis. Top line data
supports a prior proof-of-concept study which showed that HMC treatment
increased the lifespan of the lupus-prone mice. The current study
expands upon the initial results and examines how HMCs significantly
inhibit the progression of otherwise fatal glomerulonephritis. The
abstract will be presented at the Vienna Congress Center on Friday,
September 4, 2015.

“This presentation at the leading lupus meeting is an important first
step in developing potential new breakthrough treatments for
disabling autoimmune diseases like lupus nephritis, where there is no
cure available today,” said Paul K. Wotton, Ph.D., President and Chief
Executive Officer. “Our preclinical research and patent estate firmly
anchors our leading position in the development of this novel
Restorative Immunology™ platform and gives Ocata the ability
to partner the non-ophthalmic uses of its technology for the treatment
of devastating autoimmune diseases.”

About Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company
focused on the development and commercialization of regenerative
ophthalmology therapeutics. Ocata’s most advanced products are in
clinical trials for the treatment of Stargardt’s macular degeneration,
dry age-related macular degeneration, and myopic macular degeneration.
Ocata’s intellectual property portfolio includes pluripotent stem cell
platforms – hESC and induced pluripotent stem cell (iPSC) – and other
cell therapy research programs. For more information, visit www.ocata.com.

Forward-Looking Statements

All statements, other than historical facts, contained in this news
release, including statements regarding Ocata’s belief regarding the
potential therapeutic activity of a pluripotent stem cell-derived
product in the treatment of auto immune diseases using Ocata’s
proprietary HMC platform, Ocata’s belief that its HMC product
is well-suited for commercial scale up and its retention of therapeutic
potency, the effect of Ocata’s pre-clinical research and patent estate
on the development of its product platforms, and any other statements
about Ocata’s future expectations, beliefs, goals, plans, results or
prospects expressed by management constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995. Any statements that are not statements of historical fact
(including statements containing the words “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” and similar expressions) should
also be considered to be forward-looking statements. There are a number
of important factors that could cause actual results or events to differ
materially from those indicated by such forward-looking statements,
including: the fact that Ocata has no product revenue and no products
approved for marketing; Ocata’s limited operating history; Ocata’s need
for and limited sources of future capital; potential failures or delays
in obtaining regulatory approval of products; risks inherent in the
development and commercialization of potential products; reliance on new
and unproven technology in the development of products; the need to
protect Ocata’s intellectual property; the challenges associated with
conducting and enrolling clinical trials; the risk that the results of
clinical trials may not support Ocata’s product candidate claims; the
risk that physicians and patients may not accept or use Ocata’s
products, even if approved; Ocata’s reliance on third parties to conduct
its clinical trials and to formulate and manufacture its product
candidates; and economic conditions generally. Additional information on
potential factors that could affect our results and other risks and
uncertainties are detailed from time to time in Ocata’s periodic
reports, including the Annual Report on Form 10-K for the fiscal year
ended December 31, 2014. Forward-looking statements are based on the
beliefs, opinions, and expectations of Ocata’s management at the time
they are made, and Ocata does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or
other circumstances should change. Forward-looking statements are based
on the beliefs, opinions, and expectations of Ocata’s management at the
time they are made, and Ocata does not assume any obligation to update
its forward-looking statements if those beliefs, opinions, expectations,
or other circumstances should change. There can be no assurance that
Ocata’s future clinical trials will be successful or that the results of
previous clinical studies will lead to commercialization or products or
therapies.